2 results
Approved WMOCompleted
To assess the efficacy of the co-administration of lanreotide Autogel 120 mg(administered via deep sub-cutaneous injections every 28 days) and pegvisomant(administered at 40 to 120 mg per week via sub-cutaneous injection given once ortwice a week)…
Approved WMORecruiting
In this study, we look at how safe the new medicinal product rusfertide is for the treatment of Polycythemia vera. And how well it works.